source
- Experts discuss mutation testing and patient factors to guide second-line CLL therapy after BTK inhibitor resistanceA 66-year-old man who was diagnosed with chronic lymphocytic leukemia five years ago and initially had an unmutated IGHV profile without TP53 alteration has been on continuous covalent BTK inhibito…
- Daraxonrasib uniquely targets active KRAS in pancreatic cancer, says MD Anderson expertDr Shubham Pant, a professor in the Department of Gastrointestinal Medical Oncology at MD Anderson Cancer Center, explained the mechanism of daraxonrasib in a recent commentary. The oral, potent R…